MA27597A1 - Methode pour amener a cesser de fumer - Google Patents

Methode pour amener a cesser de fumer

Info

Publication number
MA27597A1
MA27597A1 MA28018A MA28018A MA27597A1 MA 27597 A1 MA27597 A1 MA 27597A1 MA 28018 A MA28018 A MA 28018A MA 28018 A MA28018 A MA 28018A MA 27597 A1 MA27597 A1 MA 27597A1
Authority
MA
Morocco
Prior art keywords
smoking
reboxetine
quit
quitting
quit smoking
Prior art date
Application number
MA28018A
Other languages
English (en)
Inventor
Erik H F Wong
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of MA27597A1 publication Critical patent/MA27597A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DEPOSANT Société dite: PHARMACIA & UPJOHN COMPANY LLC REVENDICATION DE PRIORITES US 1 Juillet 2002 60/392,893 Voir en annexe le titre de l'invention et le texte de l'abrégé Méthode pour amener à cesser de fumer Il est révélé l'utilisation de réboxétine en association avec un agent améliorant la possibilité de cesser de fumer pour amener à cesser de fumer. Il est révélé également une composition comprenant de la réboxétine et un agent améliorant la possibilité de cesser de fumer, destinée à être utilisée pour amener à cesser de fumer. Des exemples d'agents améliorant la possibilité de cesser de fumer comprennent la nicotine, un antidépresseur, un antagoniste du récepteur de nicotine et un antagoniste des opioïdes.
MA28018A 2002-07-01 2004-12-17 Methode pour amener a cesser de fumer MA27597A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39289302P 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
MA27597A1 true MA27597A1 (fr) 2005-11-01

Family

ID=30000949

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28018A MA27597A1 (fr) 2002-07-01 2004-12-17 Methode pour amener a cesser de fumer

Country Status (22)

Country Link
US (1) US20040102440A1 (fr)
EP (1) EP1534254A2 (fr)
JP (1) JP2005531631A (fr)
CN (1) CN1665511A (fr)
AP (1) AP2004003188A0 (fr)
AU (1) AU2003253609A1 (fr)
BR (1) BR0312293A (fr)
CA (1) CA2491549A1 (fr)
EA (1) EA200401584A1 (fr)
EC (1) ECSP045517A (fr)
HR (1) HRP20041194A2 (fr)
IL (1) IL165882A0 (fr)
IS (1) IS7600A (fr)
MA (1) MA27597A1 (fr)
MX (1) MXPA05000296A (fr)
NO (1) NO20045535L (fr)
OA (1) OA12878A (fr)
PL (1) PL373620A1 (fr)
RS (1) RS115204A (fr)
TN (1) TNSN04267A1 (fr)
WO (1) WO2004002463A2 (fr)
ZA (1) ZA200410339B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE60313216T2 (de) 2002-12-20 2008-01-03 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
JP4343948B2 (ja) 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすための組成物
EP1870096A3 (fr) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions pour influencer la perte de poids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
CA2630624C (fr) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions et procedes d'augmentation de la sensibilite a l'insuline
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
KR20160072276A (ko) 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
WO2009004621A1 (fr) * 2007-07-02 2009-01-08 Technion Research & Development Foundation Ltd. Compositions, articles et procédés comprenant des ligands de tspo destinés à prévenir ou réduire un dommage lié au tabac
CA2725930A1 (fr) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Procedes pour traiter des pathologies des graisses viscerales
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20110046116A1 (en) 2009-08-20 2011-02-24 Cukrowski Walter J Sedative for use during eye surgery
CA2776160A1 (fr) * 2009-09-30 2011-04-07 Harlan Clayton Bieley Arreter de fumer avec maintien du poids corporel et complement nutritionnel
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
TW201217526A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Chimeric clotting factors
EA201492175A1 (ru) 2012-06-06 2015-10-30 Орексиджен Терапьютикс, Инк. Способы лечения избыточного веса и ожирения
WO2015054730A1 (fr) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions et procédés pour les administrer
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3082816B1 (fr) 2013-12-20 2019-03-20 Indivior UK Limited Compositions de naloxone intranasales et leurs procédés de préparation et d'utilisation
CN104381577A (zh) * 2014-11-18 2015-03-04 安徽润康保健食品有限公司 一种具有戒烟功能的口香糖

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301164A (zh) * 1998-04-09 2001-06-27 法玛西雅厄普约翰美国公司 神经病症的新疗法
ATE283694T1 (de) * 1998-05-08 2004-12-15 Upjohn Co Neue arzneimittelkombinationen aus reboxetin und pindolol
DE60022692T2 (de) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE10004547A1 (de) * 2000-02-02 2001-08-09 Liedtke Pharmed Gmbh Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe

Also Published As

Publication number Publication date
CN1665511A (zh) 2005-09-07
MXPA05000296A (es) 2005-08-19
ECSP045517A (es) 2005-03-10
EP1534254A2 (fr) 2005-06-01
PL373620A1 (en) 2005-09-05
AU2003253609A1 (en) 2004-01-19
OA12878A (en) 2006-09-15
JP2005531631A (ja) 2005-10-20
EA200401584A1 (ru) 2005-08-25
IL165882A0 (en) 2006-01-15
BR0312293A (pt) 2005-04-12
AP2004003188A0 (en) 2004-12-31
HRP20041194A2 (en) 2005-06-30
WO2004002463A3 (fr) 2004-02-19
CA2491549A1 (fr) 2004-01-08
IS7600A (is) 2004-12-16
ZA200410339B (en) 2006-07-26
WO2004002463A2 (fr) 2004-01-08
US20040102440A1 (en) 2004-05-27
RS115204A (en) 2007-02-05
NO20045535L (no) 2005-01-27
TNSN04267A1 (fr) 2007-03-12

Similar Documents

Publication Publication Date Title
MA27597A1 (fr) Methode pour amener a cesser de fumer
GB0504828D0 (en) Therapeutic agents
EP1199069A3 (fr) Utilisation d'un agoniste/antagonist estrogènique pour évaluer, améliorer ou maintenir la santé urogénitale
NO20022657L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og en 5-HT<N>2C</N>-antagonist, invers agonist eller delvis agonist
WO2007089318A3 (fr) Compositions et méthodes de réduction de la boulimie
DE602004021921D1 (de) Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
HUP0203677A2 (hu) Muszkarin receptor antagonista aktivitással rendelkező karbamid vegyületek
WO2004047838A3 (fr) Composition pharmaceutique a base d'agonistes des recepteurs beta-3-adrenergiques et d'antimuscariniques
MA27141A1 (fr) DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
WO2007022924A3 (fr) Compositions pharmaceutiques contenant des agents reducteurs de la viscosite a point de fusion et leur procede d'elaboration
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
CL2004000643A1 (es) Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana.
ATE265209T1 (de) Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
EA200700367A1 (ru) Новые производные 4-бензилиденпиперидина
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
TW200604165A (en) Novel benzyl(idene)-lactam derivatives
MX2007004976A (es) Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
ID23191A (id) Bentuk polimorfik dari antagonis reseptor takikinin
KR970701544A (ko) 5-HT_2 길항제를 사용하는 강박반응의 치료법(Treatment of obsessive-compulsive disorders with 5-HT_2 antagonists)
DE60302157D1 (de) Opioidrezeptorantagonisten
DE602004024188D1 (de) Des opioid-rezeptors
TW200508203A (en) 3-azabicyclo 3.2.1 octane derivatives
HUP0100959A2 (hu) Vizes készítmény parazita rovarok és atkák emberen történő irtására
WO2005113535A3 (fr) Derives pyrazinylmethyle-lactame